Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis

Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis

We investigated the diagnostic performance of Somatostatin Receptor Positron Emission Tomography/Computed Tomography (SSR-PET/CT) for the detection of primary lesion and initial staging of pancreatic neuroendocrine tumors (pNETs). A comprehensive literature search up to January 2020 was performed se...

Full description

Bibliographic Details
Main Authors:	Matteo Bauckneht, Domenico Albano, Salvatore Annunziata, Giulia Santo, Priscilla Guglielmo, Viviana Frantellizzi, Alessia Branca, Cristina Ferrari, Antonio Vento, Alessia Mirabile, Anna Giulia Nappi, Laura Evangelista, Pierpaolo Alongi, Riccardo Laudicella
Format:	Article
Language:	English
Published:	MDPI AG 2020-08-01
Series:	Diagnostics
Subjects:	pancreas neuroendocrine tumors positron emission tomography somatostatin receptor analogs
Online Access:	https://www.mdpi.com/2075-4418/10/8/598

Similar Items

[89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors
by: Alexis M. Sanwick, et al.
Published: (2024-12-01)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
by: Fernando Sebastian-Valles, et al.
Published: (2023-03-01)

Crosstalk of TGF-β and somatostatin signaling in adenocarcinoma and neuroendocrine tumors of the pancreas: a brief review
by: Hendrik Ungefroren, et al.
Published: (2025-03-01)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
by: Maria Isabel del Olmo-Garcia, et al.
Published: (2021-12-01)

Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells
by: Valentina Rossi, et al.
Published: (2024-12-01)

Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia
by: Ludovica Magi, et al.
Published: (2021-01-01)

Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients
by: Mehmet Muhittin Yalçın, et al.
Published: (2024-10-01)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
by: Kristof Harda, et al.
Published: (2020-12-01)

EXPRESSION OF INSULIN, GLUCAGON, SOMATOSTATIN, AND PANCREATIC POLYPEPTIDE IN THE PANCREAS OF THE EURASIAN MOORHEN (Gallinula chloropus)
by: Ahmed Abdellatif
Published: (2023-07-01)

Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
by: Karolina Morawiec-Sławek, et al.
Published: (2024-11-01)

Efficacy and predictors of response to somatostatin analogues in patients with ectopic ACTH syndrome
by: Olga O. Golounina, et al.
Published: (2024-12-01)

“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy
by: Sara Massironi, et al.
Published: (2025-02-01)

Evaluation of a New <sup>177</sup>Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5
by: Rosalba Mansi, et al.
Published: (2020-09-01)

Somatostatin and Somatostatin-Containing Interneurons—From Plasticity to Pathology
by: Monika Liguz-Lecznar, et al.
Published: (2022-02-01)

SOMATOSTATIN RECEPTORS AS POTENTIALTHERAPEUTIC TARGETS IN THE TREATMENT OF ADVANCED ADRENOCORTICAL CANCER. A CASE REPORT
by: A. A. Kolomeytseva, et al.
Published: (2018-05-01)

Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues
by: Manwar A. Mohammed AL-Naqqash
Published: (2016-01-01)

Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?
by: Çağlagül Erol, et al.
Published: (2022-08-01)

Research Progress of Metal-Based Radiopharmaceuticals Targeting Somatostatin Receptor
by: QIN Xiang-yu, et al.
Published: (2023-04-01)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
by: Romain Eychenne, et al.
Published: (2020-09-01)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
by: Jasminka Hasic Telalovic, et al.
Published: (2021-04-01)

Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias
by: Argyrios Periferakis, et al.
Published: (2024-09-01)

Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors
by: Joo Young Kim, et al.
Published: (2024-02-01)

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
by: Leonidas N. Diamantopoulos, et al.
Published: (2023-07-01)

Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan
by: Jen-Shi Chen, et al.
Published: (2024-08-01)

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Blanked Out Pulmonary Neuroendocrine Tumor
by: Muhammed Yaman Swied, et al.
Published: (2024-05-01)

Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study
by: Tais Basaco Bernabeu, et al.
Published: (2024-10-01)

Clinical Impact of <sup>18</sup>F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review
by: Annachiara Arnone, et al.
Published: (2020-12-01)

Somatostatin Receptor Imaging in the Diagnosis and Management of Parathyroid Neuroendocrine Neoplasia
by: Uliana Tsoy, et al.
Published: (2024-12-01)

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review
by: Shista Priyadarshini, et al.
Published: (2022-07-01)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
by: Francesca Corti, et al.
Published: (2023-09-01)

Postprandial abdominal pain and weight loss as the initial presentation of abdominal neuroendocrine tumor recurrence
by: Pitchaporn Yingchoncharoen, et al.
Published: (2024-07-01)

The skin as a window to the gut: A case of carcinoid syndrome
by: Catarina Alves Costa, et al.
Published: (2024-03-01)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
by: Robert Pichler, et al.
Published: (2021-06-01)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
by: Aadil Adnan, et al.
Published: (2023-06-01)

The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review
by: Aldona Kasprzak, et al.
Published: (2024-03-01)

Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)

PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers
by: Petar Saric, et al.
Published: (2021-12-01)

Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist
by: Pooja Dasgupta, et al.
Published: (2021-10-01)

Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review
by: Anna La Salvia, et al.
Published: (2021-10-01)

Detection of cardiac neuroendocrine tumour metastases by somatostatin receptor PET/CT: a systematic review and meta-analysis
by: Daniela Campanale, et al.
Published: (2024-10-01)